Bionano Genomics, Inc. (BNGO) Q3 2024 Earnings Call Transcript Summary
Bionano Genomics, Inc. (BNGO) Q3 2024 Earnings Call Transcript Summary
GAAP gross margin was negative at 139%, affected by $9.8 million in one-time charges, while non-GAAP gross margin was 26%.The following is a summary of the Bionano Genomics, Inc. (BNGO) Q3 2024 Earnings Call Transcript:
以下是Bionano Genomics，Inc. (BNGO) 2024年第三季度業績會交易摘要：
Financial Performance:
財務表現：
Bionano reported Q3 revenue of $6.1 million, a 35% year-over-year decrease, driven primarily by a reduction in revenues from discontinued clinical services.
Non-GAAP operating expenses decreased by approximately $100 million on an annualized basis due to strategic reductions in headcount and other cost-saving measures.
GAAP gross margin was negative at 139%, affected by $9.8 million in one-time charges, while non-GAAP gross margin was 26%.
Operating cash burn was reduced by 46% year-over-year to approximately $14 million.
Bionano報告第三季度營業收入爲610萬美元，同比下降35％，主要受到終止臨床服務收入減少的影響。
非GAAP營業費用按年計降低約10000萬美元，主要是由於戰略性裁員和其他節約成本措施。
GAAP毛利率達到負139％，受980萬美元的一次性費用影響，而非GAAP毛利率爲26％。
經營性現金淨流出同比減少46％，至約1400萬美元。
Business Progress:
業務進展：
Bionano focused on increasing the utilization of optical genome mapping in cytogenetics, particularly for karyotyping and FISH alternatives.
Significant advancements in the Stratys system with continued demand and shipments, emphasizing the system's higher throughput capabilities.
Continuity and expansion of clinical studies, particularly in hematological malignancies, with ongoing efforts to advance trials led by key sites.
Initiative for reimbursement of optical genome mapping is progressing with a new CPT code established, awaiting final pricing.
Bionano專注於提高光學基因組測序在細胞遺傳學中的應用，尤其是染色體核型和FISH替代方案。
Stratys系統取得重大進展，需求和出貨持續增加，強調系統更高的吞吐能力。
在血液惡性腫瘤方面，臨床研究持續擴展，重點是通過主要研究站點推進試驗的連續性和擴展。
爲光學基因組測序的報銷倡議正在進展，已制定新的CPt碼，等待最終價格的確定。
Opportunities:
機會：
Gradual return to growth in consumable sales, particularly OGM consumables for routine use.
Expansion in the utility and adoption of optical genome mapping as standard for certain applications, such as analysis of hematological malignancies and constitutional genetic diseases.
耗材銷售逐漸恢復增長，尤其是用於常規用途的OGm耗材。
光學基因組測序的實用性和應用範圍擴大，成爲某些應用的標準，比如分析血液惡性腫瘤和遺傳性疾病。
Risks:
風險：
The transition to a new go-to-market strategy and reduction in operating expenses introduces challenges and affects short-term financial results with several one-time transitory charges.
Delays in system sales due to underestimated approval times by some customers.
轉變爲新的營銷策略和營業費用的削減引入挑戰，對短期財務業績產生影響，額外增加了幾項一次性過渡性費用。
由於一些客戶審批時間被低估，系統銷售出現延遲。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
